Literature DB >> 19101005

Characterization of dengue complex-reactive epitopes on dengue 3 virus envelope protein domain III.

Kiyohiko Matsui1, Gregory D Gromowski, Li Li, Amy J Schuh, J Ching Lee, Alan D T Barrett.   

Abstract

The disease dengue (DEN) is caused by four genetically and serologically related viruses termed DENV-1, -2, -3, and -4. The DENV envelope (E) protein ectodomain can be divided into three structural domains designated ED1, ED2, and ED3. The ED3 contains the DENV type-specific and DENV complex-reactive (epitopes shared by DENV 1-4) antigenic sites. In this study the epitopes recognized by four DENV complex-reactive monoclonal antibodies (MAbs) with neutralizing activity were mapped on the DENV-3 ED3 using a combination of physical and biological techniques. Amino acid residues L306, K308, G381, I387, and W389 were critical for all four MAbs, with residues V305, E309, V310, K325, D382, A384, K386, and R391 being critical for various subsets of the MAbs. A previous study by our group (Gromowski, G.D., Barrett, N.D., Barrett, A.D., 2008. Characterization of dengue complex-specific neutralizing epitopes on the envelope protein domain III of dengue 2 virus. J. Virol 82, 8828-8837) characterized the same panel of MAbs with DENV-2. The location of the DENV complex-reactive antigenic site on the DENV-2 and DENV-3 ED3s is similar; however, the critical residues for binding are not identical. Overall, this indicates that the DENV complex-reactive antigenic site on ED3 may be similar in location, but the surprising result is that DENV 2 and 3 exhibit unique sets of residues defining the energetics of interaction to the same panel of MAbs. These results imply that the amino acid sequences of DENV define a unique interaction network among these residues in spite of the fact that all flavivirus ED3s to date assume the same structural fold.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19101005     DOI: 10.1016/j.virol.2008.11.013

Source DB:  PubMed          Journal:  Virology        ISSN: 0042-6822            Impact factor:   3.616


  29 in total

1.  Recombinant dengue type 2 viruses with altered e protein domain III epitopes are efficiently neutralized by human immune sera.

Authors:  Wahala M P B Wahala; Claire Huang; Siritorn Butrapet; Laura J White; Aravinda M de Silva
Journal:  J Virol       Date:  2012-01-25       Impact factor: 5.103

2.  A bispecific antibody effectively neutralizes all four serotypes of dengue virus by simultaneous blocking virus attachment and fusion.

Authors:  Xin Shi; Yongqiang Deng; Huajing Wang; Guanghui Ji; Wenlong Tan; Tao Jiang; Xiaofeng Li; Hui Zhao; Tian Xia; Yanchun Meng; Chao Wang; Xiaojie Yu; Yang Yang; Bohua Li; E-De Qin; Jianxin Dai; Cheng-Feng Qin; Yajun Guo
Journal:  MAbs       Date:  2016-02-23       Impact factor: 5.857

3.  Structure and function analysis of therapeutic monoclonal antibodies against dengue virus type 2.

Authors:  Soila Sukupolvi-Petty; S Kyle Austin; Michael Engle; James D Brien; Kimberly A Dowd; Katherine L Williams; Syd Johnson; Rebeca Rico-Hesse; Eva Harris; Theodore C Pierson; Daved H Fremont; Michael S Diamond
Journal:  J Virol       Date:  2010-06-30       Impact factor: 5.103

4.  Conservation of the DENV-2 type-specific and DEN complex-reactive antigenic sites among DENV-2 genotypes.

Authors:  Trevor J Pitcher; Gregory D Gromowski; David W C Beasley; Alan D T Barrett
Journal:  Virology       Date:  2011-12-05       Impact factor: 3.616

5.  Genetic diversity and evolutionary dynamics of dengue isolates from India.

Authors:  Johni Rexliene; Jayavel Sridhar
Journal:  Virusdisease       Date:  2019-07-24

6.  PCP consensus sequences of flaviviruses: correlating variance with vector competence and disease phenotype.

Authors:  Petr Danecek; Wenzhe Lu; Catherine H Schein
Journal:  J Mol Biol       Date:  2009-12-04       Impact factor: 5.469

7.  The development of therapeutic antibodies that neutralize homologous and heterologous genotypes of dengue virus type 1.

Authors:  Bimmi Shrestha; James D Brien; Soila Sukupolvi-Petty; S Kyle Austin; Melissa A Edeling; Taekyung Kim; Katie M O'Brien; Christopher A Nelson; Syd Johnson; Daved H Fremont; Michael S Diamond
Journal:  PLoS Pathog       Date:  2010-04-01       Impact factor: 6.823

8.  Human monoclonal antibodies against West Nile virus induced by natural infection neutralize at a postattachment step.

Authors:  Matthew R Vogt; Bastiaan Moesker; Jaap Goudsmit; Mandy Jongeneelen; S Kyle Austin; Theodore Oliphant; Steevenson Nelson; Theodore C Pierson; Jan Wilschut; Mark Throsby; Michael S Diamond
Journal:  J Virol       Date:  2009-04-22       Impact factor: 5.103

9.  The Fc region of an antibody impacts the neutralization of West Nile viruses in different maturation states.

Authors:  Phong D Lee; Swati Mukherjee; Melissa A Edeling; Kimberly A Dowd; S Kyle Austin; Carolyn J Manhart; Michael S Diamond; Daved H Fremont; Theodore C Pierson
Journal:  J Virol       Date:  2013-10-09       Impact factor: 5.103

10.  Identification of continuous human B-cell epitopes in the envelope glycoprotein of dengue virus type 3 (DENV-3).

Authors:  Andréa N M Rangel da Silva; Eduardo J M Nascimento; Marli Tenório Cordeiro; Laura H V G Gil; Frederico G C Abath; Silvia M L Montenegro; Ernesto T A Marques
Journal:  PLoS One       Date:  2009-10-13       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.